CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research
May 16 2024 - 8:01AM
Business Wire
CytoReason, a pioneer in developing computational disease models
for drug development, today announced a strategic collaboration
with the Crohn’s & Colitis Foundation. The collaboration aims
to empower CytoReason’s analytical capabilities with the
Foundation’s IBD Plexus® real-world data platform. This
collaboration has the potential to accelerate new discoveries with
superior data integration and improve the precision and
effectiveness of drug development in inflammatory bowel disease
(IBD).
As part of the collaboration, the Foundation’s IBD Plexus®
real-world data platform, comprising thousands of patient
intestinal biopsies and comprehensive real-world data, will be
integrated into CytoReason’s pre-computed disease model platform.
The combination of IBD Plexus® real-world data with CytoReason’s
advanced computational capabilities will enable fine
characterization of disease subtypes, positioning of treatments and
combination therapies throughout disease subtypes, and generation
of blood-based biomarkers to facilitate clinical trials. In
addition, the collaboration will enable characterizing the
molecular trajectory of natural disease courses and differential
drug effects, which promises to deepen the IBD field's
understanding and treatment of these diseases by leveraging AI and
large-scale molecular and clinical datasets.
Prof. Yehuda Chowers, chief medical officer of
CytoReason, said, "This partnership with the Foundation is not
just a milestone for CytoReason but a leap forward for the entire
industry. By integrating the Foundation's vast datasets into our
models, we can provide deeper insights into IBD, and enable the
development of more targeted and effective therapies."
Dr. Alan Moss, chief scientific officer of the Crohn’s &
Colitis Foundation, said, “Informing CytoReason’s computational
models with extensive real-world data from IBD Plexus® allows us to
deepen our understanding of IBD at a molecular level and explore
new pathways for potential therapies. This collaboration
underscores the power of combining rich clinical and molecular data
with innovative algorithms to potentially deliver more targeted and
effective treatments for patients suffering from IBD.”
About CytoReason
CytoReason is a tech company transforming biopharma’s
decision-making from trial and error to data-driven using an AI
Platform of computational disease models. With its extensive
database of public and proprietary data, the company maps human
diseases – tissue by tissue and cell by cell. Researchers of all
levels rely on CytoReason’s technology to make data-driven
decisions across the drug development life cycle. Scientists can
identify potential targets, prioritize indications, and stratify
patient populations. Program leaders can compare drugs across
multiple diseases or multiple drugs within a single disease.
C-level executives can gain valuable tools to manage and optimize
entire drug portfolios. To learn more, visit
https://www.cytoreason.com.
About the Crohn’s & Colitis Foundation
The Crohn’s & Colitis Foundation is the leading nonprofit
organization focused on both research and patient support for
inflammatory bowel disease (IBD), with the mission of curing
Crohn’s disease and ulcerative colitis and improving the quality of
life for the millions of people living with IBD. The Foundation’s
work is dramatically accelerating the research process, while also
providing extensive educational and support resources for patients
and their families, medical professionals, and the public. To learn
more about the IBD Plexus® program, visit
https://www.crohnscolitisfoundation.org/research/plexus.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516074989/en/
Zeev Ben Shachar media@cytoreason.com